The double upgrade from a historically bearish firm is notable but tempered by middling accuracy, negative EPS revisions, and insider selling. Traders should treat this as a modest positive signal but not a strong buy catalyst, wait for confirmation from higher-accuracy firms or a reversal in EPS momentum.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 5 $391.00entry
- T+1 · 5mo ago +4.59%α +4.36% · $408.95
- T+5 · 5mo ago +3.95%α +3.38% · $406.43
- T+20 · 4mo ago +7.36%α +5.50% · $419.77
- T+60 · 3mo ago −5.90%α −9.89% · $367.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
JP Morgan double-upgraded TSLA from Underweight to Neutral on June 5, 2026, raising its price target to $475 from $145, a 228% increase. The stock trades at $418.45, implying 13.5% upside to the new target. JP Morgan has a 55% accuracy rate on 5,703 calls and average return of 5.6%, placing it in the middle tier among firms covering TSLA. Consensus is mixed: 29 Buy (71%), 23 Hold (56%), 8 Sell (20%) from 41 analysts. Mean target is $411.89, median $450, JP Morgan's $475 sits above both. Momentum is positive with 1 upgrade and 0 downgrades in 30 days, but EPS revisions are net negative: 18 downgrades vs 7 upgrades for the current fiscal year. Insider sales total ~$2.4M over two months, including a $1.35M sale by VP Taneja. Institutional activity is mixed: Renaissance Technologies doubled its position (+220.9%), while Bank of America trimmed 28.2%. Short interest is elevated at 63.1% of float. The double upgrade from a historically bearish firm is a notable shift, but JP Morgan's middling accuracy and the EPS revision headwinds temper conviction. Bottom line: the call is directionally bullish but consensus-aligned, warranting a neutral-to-slightly-positive impact adjustment.
Impact Score
Consensus & Targets
Consensus among 41 analysts: 9 Strong Buy, 20 Buy (total 71% Buy), 23 Hold (56%), 7 Sell, 1 Strong Sell (total 20% Sell). The consensus is tilted bullish but with a large hold contingent, reflecting uncertainty. JP Morgan's Neutral aligns with the hold camp, below the bullish majority.
Current price: $418.45. Mean target: $411.89 (implied downside of -1.6%). Median target: $450 (implied upside of +7.5%). High target: $600 (Wedbush). Low target: $123. JP Morgan's $475 target is above both mean and median, implying 13.5% upside, more bullish than the average analyst.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-06-05 | JP Morgan | upgrade | Neutral | $475.00 |
| 2026-06-04 | TD Cowen | reiterate | Buy | $490.00 |
| 2026-04-23 | UBS | maintain | Neutral | $364.00 |
| 2026-04-23 | Canaccord Genuity | maintain | Buy | $450.00 |
| 2026-04-23 | RBC Capital | maintain | Outperform | $475.00 |
| 2026-04-23 | TD Cowen | reiterate | Buy | $490.00 |
| 2026-04-23 | Cantor Fitzgerald | reiterate | Overweight | $510.00 |
| 2026-04-23 | Wedbush | reiterate | Outperform | $600.00 |
| 2026-04-23 | Mizuho | maintain | Outperform | $480.00 |
| 2026-04-23 | Needham | reiterate | Hold | No target |
In the last 30 days, TSLA has received 1 upgrade (JP Morgan) and 0 downgrades. EPS revision trends are negative: for the current fiscal year, 18 downgrades vs 7 upgrades in the last 30 days; for the next quarter, 14 downgrades vs 7 upgrades. Estimates are being revised lower, creating a headwind for the stock.
Firm Track Record: JP Morgan
JP Morgan accuracy: 55% on 5703 calls | avg return: 5.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 3/3 | 53.8% | top tier |
| RBC Capital | 93% | 13/14 | 33.7% | top tier |
| Piper Sandler | 85% | 11/13 | 32.7% | top tier |
| Canaccord Genuity | 80% | 12/15 | 28.5% | top tier |
| Roth MKM | 80% | 4/5 | 29.9% | top tier |
| Oppenheimer | 80% | 4/5 | 26.6% | top tier |
| Citigroup | 80% | 4/5 | 19.3% | top tier |
| Cantor Fitzgerald | 79% | 27/34 | 31.7% | top tier |
| Goldman Sachs | 79% | 11/14 | 22.5% | top tier |
| Needham | 78% | 7/9 | 24.6% | top tier |
JP Morgan has a 55% accuracy rate on 5,703 calls with an average return of 5.6%, placing it in the middle tier among TSLA analysts. Top-tier firms include Jefferies (100% on 3 calls, avg return 53.8%), RBC Capital (93% on 14 calls, avg return 33.7%), and Piper Sandler (85% on 13 calls, avg return 32.7%). JP Morgan's accuracy is below these leaders, reducing the weight of this upgrade.
Earnings Estimates
Next earnings: Jul 21, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $2.05 | $1.35 to $3.19 | $102.3B | ↑14 ↓0 |
| 0q | $0.45 | $0.26 to $0.59 | $24.6B | ↑9 ↓0 |
| +1y | $2.51 | $1.46 to $3.65 | $118.1B | ↑7 ↓0 |
| +1q | $0.54 | $0.30 to $0.83 | $26.9B | ↑7 ↓0 |
Cross-Platform Signals
Insider trades show $2.4M in sales over two months, including a $1.35M sale by VP Taneja on May 13 and two sales by director Wilson-Thompson totaling ~$1M. These are not routine 10b5-1 sales and align with the bearish side of the consensus. Institutional activity is mixed: Renaissance Technologies doubled its position (+220.9%) and Norges Bank initiated a new $17.1B stake, while Bank of America trimmed 28.2%. Short interest is elevated at 63.1% of float, indicating heavy bearish positioning. The insider sales and high short interest diverge from the bullish upgrade signal, reducing conviction.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
39 reports on TSLA
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +11.68% at T+20 after the Apr 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 20261d ago PTAB Trial Neutral 2/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 16, 20261d ago PTAB Trial Neutral 2/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 16, 20261d ago PTAB Trial Neutral 3/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 16, 20261d ago PTAB Trial Neutral 2/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 16, 20261d ago PTAB Trial Neutral 2/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 16, 20261d ago PTAB Trial Neutral 2/10 Entry $378.66 Now $390.22 +3.05% settles Nov 24
- Nov 9, 20267d ago DEFA14A Neutral 2/10 Entry $379.78 Now $390.22 +2.75% settles Nov 17
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $378.05 to $379.74 Now $390.22 +3.22% ▲ +0.45% +2.14% vs SPY
- Nov 4, 202613d ago Court Ruling Neutral 2/10 Entry $343.69 to $397.45 Now $390.22 +13.54% ▲ +15.64% +12.35% vs SPY
- Nov 3, 202614d ago Court Ruling Neutral 2/10 Entry $385.19 to $390.84 Now $390.22 +1.31% ▲ +1.47% +2.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers